Dong‐Jing Fu

3.5k total citations · 1 hit paper
66 papers, 1.7k citations indexed

About

Dong‐Jing Fu is a scholar working on Psychiatry and Mental health, Pharmacology and Experimental and Cognitive Psychology. According to data from OpenAlex, Dong‐Jing Fu has authored 66 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Psychiatry and Mental health, 25 papers in Pharmacology and 17 papers in Experimental and Cognitive Psychology. Recurrent topics in Dong‐Jing Fu's work include Schizophrenia research and treatment (29 papers), Treatment of Major Depression (25 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (16 papers). Dong‐Jing Fu is often cited by papers focused on Schizophrenia research and treatment (29 papers), Treatment of Major Depression (25 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (16 papers). Dong‐Jing Fu collaborates with scholars based in United States, Belgium and China. Dong‐Jing Fu's co-authors include Larry Alphs, Carla M. Canuso, Charles R. Cantor, Hubert Köster, Rosanne Lane, Kai Tang, Andreas Braun, Ibrahim Turkoz, Wayne C. Drevets and Dawn F. Ionescu and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

Dong‐Jing Fu

64 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression

2023 110 citations Andreas Reif, István Bitter et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dong‐Jing Fu United States	21	608	587	412	335	225	66	1.7k
Jurjen J. Luykx Netherlands	26	182 0.3×	726 1.2×	231 0.6×	253 0.8×	384 1.7×	138	1.9k
C.W. Gerth Germany	14	1.4k 2.3×	425 0.7×	435 1.1×	404 1.2×	144 0.6×	16	2.3k
Adam Savitz United States	23	160 0.3×	947 1.6×	447 1.1×	107 0.3×	261 1.2×	75	2.1k
Sergi Mas Spain	25	130 0.2×	530 0.9×	464 1.1×	230 0.7×	344 1.5×	115	1.8k
Linda Beauclair Canada	22	330 0.5×	1.1k 1.9×	345 0.8×	94 0.3×	276 1.2×	43	2.1k
Patrizia Cavazzoni United States	22	275 0.5×	1.3k 2.2×	250 0.6×	148 0.4×	214 1.0×	42	1.9k
Karu Jayathilake United States	20	245 0.4×	1.1k 1.9×	501 1.2×	261 0.8×	245 1.1×	42	2.1k
Н. Г. Незнанов Russia	14	166 0.3×	353 0.6×	502 1.2×	233 0.7×	130 0.6×	123	1.5k
Vı́ctor Navarro Spain	22	225 0.4×	248 0.4×	332 0.8×	75 0.2×	82 0.4×	64	1.6k
Amàlia Lafuente Spain	28	136 0.2×	465 0.8×	910 2.2×	290 0.9×	247 1.1×	111	2.3k

Countries citing papers authored by Dong‐Jing Fu

Since Specialization

Citations

This map shows the geographic impact of Dong‐Jing Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dong‐Jing Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dong‐Jing Fu more than expected).

Fields of papers citing papers by Dong‐Jing Fu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dong‐Jing Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dong‐Jing Fu. The network helps show where Dong‐Jing Fu may publish in the future.

Co-authorship network of co-authors of Dong‐Jing Fu

This figure shows the co-authorship network connecting the top 25 collaborators of Dong‐Jing Fu. A scholar is included among the top collaborators of Dong‐Jing Fu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dong‐Jing Fu. Dong‐Jing Fu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kosik‐Gonzalez, Colette, Dong‐Jing Fu, Rosanne Lane, et al.. (2025). Effect of Esketamine on Depressive Symptoms in Adolescents With Major Depressive Disorder at Imminent Suicide Risk: A Randomized Psychoactive-Controlled Study. Journal of the American Academy of Child & Adolescent Psychiatry. 65(1). 42–55. 3 indexed citations

Janik, Adam, et al.. (2024). Efficacy and safety of esketamine nasal spray as monotherapy in adults with treatment-resistant depression: a randomized, double-blind, placebo-controlled study. Neuroscience Applied. 3. 105279–105279. 1 indexed citations

Li, Zhenhao, Ting Xu, Yajuan Zhang, et al.. (2024). Dynamic changes in body composition during XELOX/SOX chemotherapy in patients with gastric cancer. Frontiers in Oncology. 14. 1309681–1309681. 1 indexed citations

Wang, Lien, Xiaowei Chen, Heidi De Smedt, et al.. (2023). A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics. Neuropsychiatric Disease and Treatment. Volume 19. 2857–2870.

Reif, Andreas, István Bitter, Jozefien Buyze, et al.. (2023). Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. New England Journal of Medicine. 389(14). 1298–1309. 110 indexed citations breakdown →

Fu, Dong‐Jing, et al.. (2023). Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality. BMC Psychiatry. 23(1). 587–587. 10 indexed citations

Chen, Li, Rosanne Lane, Wayne C. Drevets, et al.. (2023). Long-term safety and maintenance of response with esketamine nasal spray in participants with treatment-resistant depression: interim results of the SUSTAIN-3 study. Neuropsychopharmacology. 48(8). 1225–1233. 69 indexed citations

Hou, Xuan, et al.. (2023). Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant in Adult Patients with Treatment-Resistant Depression: A Randomized, Double-Blind, Multicenter, Active-Controlled Study Conducted in China and USA. Neuropsychiatric Disease and Treatment. Volume 19. 693–707. 24 indexed citations

Canuso, Carla M., Dawn F. Ionescu, Xiang Li, et al.. (2021). Esketamine Nasal Spray for the Rapid Reduction of Depressive Symptoms in Major Depressive Disorder With Acute Suicidal Ideation or Behavior. Journal of Clinical Psychopharmacology. 41(5). 516–524. 51 indexed citations

10.

Fu, Dong‐Jing, Dawn F. Ionescu, Xiang Li, et al.. (2020). Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent. The Journal of Clinical Psychiatry. 81(3). 148 indexed citations

11.

Alphs, Larry, Dong‐Jing Fu, David J. Williamson, et al.. (2020). Suicide Ideation and Behavior Assessment Tool (SIBAT): Evaluation of Intra- and Inter-Rater Reliability, Validity, and Mapping to Columbia Classification Algorithm of Suicide Assessment. Psychiatry Research. 294. 113495–113495. 20 indexed citations

12.

Fu, Dong‐Jing, Ibrahim Turkoz, David P. Walling, et al.. (2017). Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder. Schizophrenia Research. 192. 185–193. 14 indexed citations

13.

Li, Qingqin S., Nathan E. Wineinger, Dong‐Jing Fu, et al.. (2016). Genome-wide association study of paliperidone efficacy. Pharmacogenetics and Genomics. 27(1). 7–18. 36 indexed citations

14.

Young‐Xu, Yinong, Mei Sheng Duh, Erik Muser, et al.. (2016). Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia. The Journal of Clinical Psychiatry. 77(10). e1332–e1341. 22 indexed citations

15.

Joshi, Kruti, Jay Lin, Melissa Lingohr-Smith, & Dong‐Jing Fu. (2015). Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder. Journal of Medical Economics. 18(8). 629–636. 7 indexed citations

16.

Alphs, Larry, et al.. (2014). Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia. Expert Opinion on Pharmacotherapy. 15(7). 1029–1042. 7 indexed citations

17.

Markowitz, Michael A., Dong‐Jing Fu, Bennett Levitan, et al.. (2013). Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies. Annals of General Psychiatry. 12(1). 22–22. 28 indexed citations

18.

Turkoz, Ibrahim, Dong‐Jing Fu, Cynthia A. Bossie, John J. Sheehan, & Larry Alphs. (2013). Relationship between the clinical global impression of severity for schizoaffective disorder scale and established mood scales for mania and depression. Journal of Affective Disorders. 150(1). 17–22. 14 indexed citations

19.

Bossie, Cynthia A., et al.. (2011). Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry. 11(1). 79–79. 29 indexed citations

20.

Yeh, Doreen DeFaria, et al.. (2011). Clinical factors and echocardiographic techniques related to the presence, size, and location of acoustic windows for leadless cardiac pacing. EP Europace. 13(12). 1760–1765. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact